Alseres Pharmaceuticals to Host 2007 3rd Quarter Conference Call
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
To access the conference call, please dial 877-741-4239 for domestic and719-325-4839 international. The code for this conference call is 3796954.Please dial in 5 to 10 minutes prior to the scheduled start time. A replay ofthe call will be posted on the Investor Relations section of the website,www.alseres.com, within 48 hours following the conference call and will beavailable through Thursday, November 29th, 2007.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology companyengaged in developing breakthrough regenerative therapeutics to treattraumatic injuries and degenerative diseases. The Company maintains aworld-class intellectual property position in the field of regenerativetherapeutics. Our energy and focus is reflected in several importantinitiatives. Cethrin(R), a recombinant-protein-based drug designed to promotenerve repair after acute spinal cord injury, demonstrated positive interimresults in a Phase I/IIa clinical trial. The Company's research andpre-clinical programs include, Inosine for the treatment of spinal cord injuryand stroke, Oncomodulin for the treatment of ocular injury and disease andresearch programs directed at a number of regenerative therapies includingbone repair. The company has a robust molecular imaging development programtargeting diagnosis of Parkinson's disease and potentially dementia and ADHD.Our lead product candidate is ALTROPANE(R) which is in Phase III clinicaltrials for the diagnosis of Parkinson's disease. Alseres has researchcollaborations with Harvard Medical School and Children's Hospital Boston.
The foregoing release contains certain forward-looking statements withinthe meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements include statements regarding AlseresPharmaceuticals' future expectations, beliefs, intentions, goals, strategies,plans or prospects regarding the future, including the development andcommercialization of ALTROPANE and Cethrin, the prospects of the Company's CNStherapeutics program, the Company's strategies to develop and commercializeaxon regeneration technologies and the breadth of the Company's technologiesand intellectual property portfolio. Forward-looking statements can beidentified by terminology such as "anticipate," "believe," "could," "couldincrease the likelihood," "estimate," "expect," "intend," "is planned," "may,""should," "will," "will enable," "would be expected," "look forward," "mayprovide," "would" or similar terms, variations of such terms or the negativeof those terms. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors including those risks, uncertaintiesand factors referred to in the Company's Quarterly Report on Form 10-Q for thequarter ended June 30, 2007 filed with the Securities and Exchange Commissionunder the section "Risk Factors," as well as other documents that may be filedby Alseres Pharmaceuticals from time to time with the Securities and ExchangeCommission. As a result of such risks, uncertainties and factors, theCompany's actual results may differ materially from any future results,performance or achievements discussed in or implied by the forward-lookingstatements contained herein. Alseres Pharmaceuticals is providing theinformation in this press release as of this date and assumes no obligationsto update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext 224Alseres Pharmaceuticals, Inc. email@example.com
You May Also Like